Lymphoma & Plasma Cell Disorders
Conference Coverage
Omidubicel improves on umbilical cord blood transplants
Feature
FDA scrutinizes cancer therapies granted accelerated approval
From the Journals
High-dose chemo no better than standard dose for B-cell lymphoma
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
From the Journals
New inhibitor shows promise in previously failed B-cell malignancies
Pirtobrutinib (formerly known as LOXO-305) is an oral-dose, highly selective, reversible inhibitor.
Clinical Insights
mCODE: Improving data sharing to enhance cancer care
From the Journals
‘Phenomenal’ results with CAR T cells in R/R multiple myeloma
Conference Coverage
Maribavir seen as superior to other antivirals for CMV clearance post transplant
Conference Coverage
Using engineered T cells reduced acute, chronic GVHD
Conference Coverage
Novel ddPCR assay precisely measures CAR T-cells after infusion
Conference Coverage
Steroid complications in GVHD common, boost costs of care